TNFRSF8
Tumor necrosis factor receptor superfamily member 8
As of the edition of 20 October 2026, TNFRSF8 (tumor necrosis factor receptor superfamily member 8, UniProt P28908) has 7 drugs tested at it and 5 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P28908
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 2
- Disease areas
- Cancer; Immune system; Blood and lymph; Skin and connective tissue; Urinary and reproductive; Infections; Hormones; Lungs and airways
- Registered trials of its drugs
- 188
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Brentuximab vedotin | Marketed | Phase 4 | Ends 2029 |
| SGN-30 | Stopped | Phase 2 | none listed |
| Iratumumab | Stopped | Phase 2 | none listed |
| HEFI-1 | Went quiet | Phase 1 | none listed |
| F0002-ADC | Status not established | Phase 1 | none listed |
| GEN3017 | Stopped | Phase 2 | none listed |
| PF-08046045 | Stopped | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Undetermined | 1 |
| Total on the list | 5 |
The other 2 companies at TNFRSF8
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at TNFRSF8, ranked, with the facts behind eachRequest access. Nothing is shown until you do.